OA10954A - Hiv envelope polypeptides and vaccine - Google Patents

Hiv envelope polypeptides and vaccine Download PDF

Info

Publication number
OA10954A
OA10954A OA9900004A OA9900004A OA10954A OA 10954 A OA10954 A OA 10954A OA 9900004 A OA9900004 A OA 9900004A OA 9900004 A OA9900004 A OA 9900004A OA 10954 A OA10954 A OA 10954A
Authority
OA
OAPI
Prior art keywords
thr
asn
lys
ile
val
Prior art date
Application number
OA9900004A
Other languages
English (en)
Inventor
Philip W Berman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of OA10954A publication Critical patent/OA10954A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
OA9900004A 1996-07-08 1999-01-06 Hiv envelope polypeptides and vaccine OA10954A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08

Publications (1)

Publication Number Publication Date
OA10954A true OA10954A (en) 2001-10-25

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900004A OA10954A (en) 1996-07-08 1999-01-06 Hiv envelope polypeptides and vaccine

Country Status (13)

Country Link
US (1) US6090392A (Direct)
EP (1) EP0942988A1 (Direct)
JP (1) JP2000515368A (Direct)
AP (1) AP1282A (Direct)
AU (1) AU727107B2 (Direct)
CA (1) CA2259965A1 (Direct)
ID (1) ID17767A (Direct)
IL (2) IL127701A0 (Direct)
NZ (1) NZ333500A (Direct)
OA (1) OA10954A (Direct)
TW (1) TWI221846B (Direct)
WO (1) WO1998001564A1 (Direct)
ZA (1) ZA975889B (Direct)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2903999A (en) 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
CN1635876A (zh) 2000-02-04 2005-07-06 杜克大学 人免疫缺陷病毒疫苗
WO2001083535A2 (en) * 2000-05-02 2001-11-08 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
AU2001291049A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
AU2001291050A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
US20060116325A1 (en) * 2001-02-15 2006-06-01 Oleg Chertov Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
EP1578766B1 (en) * 2002-12-03 2013-02-13 University of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US20050025779A1 (en) * 2003-06-12 2005-02-03 Vaxgen, Inc. HIV-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
EP1692516B1 (en) * 2003-10-24 2010-12-01 Immunaid Pty Ltd Method of therapy
US20080248022A1 (en) * 2004-09-08 2008-10-09 Immunaid Pty Ltd Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
EP1794327B1 (en) * 2004-09-14 2016-11-30 Argos Therapeutics, Inc. Strain independent amplification of pathogens and vaccines thereto
JP2009509970A (ja) * 2005-09-22 2009-03-12 プロサイ インコーポレイテッド 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
US8221981B2 (en) * 2007-07-30 2012-07-17 Argos Therapeutics, Inc. Primers and probes for the amplification and detection of HIV Gag, Rev and Nef polynucleotides
CN102123724B (zh) 2008-06-19 2018-05-01 变异生技公司 治疗流行性感冒的组合物和方法
DK2435825T3 (en) 2009-05-27 2015-10-19 Biotempus Ltd Modes for medical care
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
ATE151638T1 (de) * 1987-02-20 1997-05-15 Genentech Inc Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
WO1991004273A2 (en) * 1989-09-22 1991-04-04 Idec Pharmaceuticals Corp. Novel peptides associated with the cd4 binding region of gp120 and their methods of use
AU7676891A (en) * 1990-04-03 1991-10-30 Genentech Inc. Hiv envelope polypeptides
EP0527760B1 (en) * 1990-04-03 1995-07-19 Genentech, Inc. Methods and compositions for vaccination against hiv
WO1994028929A1 (en) * 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides

Also Published As

Publication number Publication date
US6090392A (en) 2000-07-18
ZA975889B (en) 1998-02-23
NZ333500A (en) 2000-09-29
EP0942988A1 (en) 1999-09-22
IL127701A (en) 2006-08-01
TWI221846B (en) 2004-10-11
IL127701A0 (en) 1999-10-28
AU727107B2 (en) 2000-11-30
WO1998001564A1 (en) 1998-01-15
AP9901432A0 (en) 1999-03-31
CA2259965A1 (en) 1998-01-15
JP2000515368A (ja) 2000-11-21
ID17767A (id) 1998-01-22
AP1282A (en) 2004-06-09
AU3567797A (en) 1998-02-02

Similar Documents

Publication Publication Date Title
OA10954A (en) Hiv envelope polypeptides and vaccine
AU700371B2 (en) Hiv envelope polypeptides
US5643756A (en) Fusion glycoproteins
Cho et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
AU704309B2 (en) Antigenically-marked non-infectious retrovirus-like particles
JP4749481B2 (ja) 弱毒化された非機能性ｖｉｆタンパク質による免疫応答性誘導
US6585979B1 (en) HIV envelope polypeptides and immunogenic composition
JPH10506008A (ja) ＨＩＶ−１ Ｖｐｒ 融合分子に基づいたＨＩＶビリオン中へのタンパク質ターゲッティング
EP1038001B1 (en) Constitutive expression of non-infectious hiv-like particles
IE921875A1 (en) Vaccine and treatment method for human immunodeficiency¹virus
JP2009511623A (ja) レンチウイルスベクターベースのワクチン
JPH02211881A (ja) ＨＩＶに対する中和抗体を誘発するかまたはかかる抗体によって認識され得る免疫原配列を含むＨＢｓＡｇ抗原の形態学的特徴を有する組換えハイブリッドＨＢｓＡｇ粒子、かかる粒子をコードするヌクレオチド配列及び核粒子を含むワクチン
DE60125927T2 (de) Impfstoffe gegen hiv
US7524927B2 (en) Compositions, method and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions
US7090848B1 (en) HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
EP1183383B1 (en) Siv-based packaging-deficient vectors
von Brunn et al. Genetically engineered HIV type 1 peptides as tools for the determination of anti-V3 loop antibody titers in sera from HIV type 1-infected patients